glucuronyl-glucosamine-glycan-sulfate and Hyperlipidemias

During arterial hypertension it is often possible to find other factors like lipoidoproteinosis and peripheral arterial disease (POAD), which can accentuate blood rheological abnormalities in hypertensive subjects. A group of hypertensives with lipoidoproteinosis (LP) and POAD were therefore examined to evaluate the relationship between these factors and blood rheological disorders and, if possible, to correct it.. We studied a group of 27 hypertensives with LP and POAD (15 males and 12 females in menopause for at least 1 year, aged 48 +/- 4 years), with WHO stage I hypertension, obesity (BMI = 30 +/- 2), stage II type "a" POAD, class 2 type "b" lipoidoproteinosis (acc. to Fredrick-son's classification) and hyperfibrinogenemia. All patients received oral medication with 500 lipidic units (ULS) sulodexide a day, 20 mg pravastatin o.d. orally, and were put on a low-salt and low-calorie diet (1400 kcal/day) during a follow-up of 60 days. Blood rheology status was evaluated before and after treatment (red blood cell--RBC--deformability and aggregability) using a new computerized instrument, which uses laser rays: the laser assisted optical rotational red cell analyzer (LORCA) (acc. to Hardeman) and RBC deformability using optical microscopy under immersion (acc. to Zipursky and Forconi). Transcutaneous oxymetry was also used to evaluate tissue oxygenation.. At the end of the study a significant improvement (p < 0.01) was noted in the blood rheological patterns of peripheral perfusion and tissue oxygenation. This underlined the positive influence of sulodexide with pravastatin in improving hemorheological patterns and modulating hypercholesterolemia and hyperfibrogenemia in hypertensives with POAD II "a" and LP 2 "b" and blood rheology disorders.

Topics: Adult; Aged; Blood Gas Monitoring, Transcutaneous; Female; Glycosaminoglycans; Hemorheology; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Laser-Doppler Flowmetry; Lasers; Lipoid Proteinosis of Urbach and Wiethe; Male; Middle Aged; Peripheral Vascular Diseases; Pravastatin

The ability of glycosaminoglycans to bind to a wide number of biologically active macromolecules has already been investigated. Recent clinical trials on the possible therapeutic benefits of glycosaminoglycans must be placed in perspective, even if they appear to be particularly encouraging, especially as regards the glycosaminoglycan effects on certain coagulation factors. A multicenter, medium-term, double-blind, crossover trial was performed by several Italian Lipid Clinics to determine whether administration of a medium molecular weight glycosaminoglycan (Sulodexide) has a significant clinical effect. Patients affected by peripheral vascular disease and/or hyperlipidemia (type IIa, IIb and IV) were submitted to a 4-week wash-out period, followed by parenteral Sulodexide (S) or placebo (P) administration for 2 weeks, another 2 week wash-out period, parenteral crossover drug or P administration for 2 weeks and, finally, oral S administration for 6 months. Sulodexide lowered plasma viscosity and plasma fibrinogen in all patients. There was also a drop in triglycerides together with a rise in apo A-I and HDL-C in type IV hyperlipoproteinemics, whereas there was no significant effect on total or LDL-plasma cholesterol in type IIa and IIb patients. Moreover, there was a percent increase in peak flow and rest flow in the lower limbs of peripheral vascular disease patients. No side effects or intolerance phenomena were detected. The results indicate that Sulodexide administration may be useful in long-term treatment of patients with peripheral vascular disease and a concomitant increase in plasma triglycerides and/or fibrinogen and/or viscosity.

Topics: Adult; Aged; Blood Viscosity; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Erythrocyte Deformability; Female; Fibrinogen; Glycosaminoglycans; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Triglycerides

The effects of 3-glucosaminoglycan sulfate on lipids and the hemorheologic parameters were observed in a preliminary double-blind crossover study in 30 hyperlipidemic peripheral vascular disease (PVD) patients. Parenteral administration of the test drug was associated with a reduction in serum lipids, especially in triglyceride levels, and a lowering of fibrinogen, plasma viscosity, and whole blood viscosity levels. These effects justify the drug's use in the treatment of PVD, especially when associated with hypertriglyceridemia and hemorheologic disturbances.

Topics: Adult; Arteriosclerosis; Blood Viscosity; Double-Blind Method; Female; Fibrinogen; Glycosaminoglycans; Humans; Hyperlipidemias; Lipids; Male; Middle Aged

Thirty vasculopathic subjects with hyperlipoproteinemia (18) and/or diabetes (22) underwent a clinical double-blind study in order to evaluate the effect of sulodexide on lipid and hemorheologic parameters. The experimental design consisted of a first 20-day i.m. therapeutic period with either sulodexide (300 Lipasemic Units twice daily via intramuscular route) or placebo and the following 70 days with the active compound for both groups at the same posology. Results obtained demonstrated that sulodexide yields a hypotriglyceridemic effect on type IV hyperlipoproteinemia and hypofibrinogenic effect, as well. Moreover, this compound exerted a beneficial effect on HDL Cholesterol levels and on the antithrombin III activity by increasing both parameters significantly. Signs and symptoms were alleviated, particularly in the most severe cases of peripheral vascular disease. Insignificant and slight changes were observed at the end of treatments as regards the efficacy of the two administration routes, the i.m. one being more efficacious on lipid parameters and faster acting. No side effects or intolerance were observed during the different periods of the trial.

Topics: Adult; Aged; Antithrombin III; Cholesterol, HDL; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Fibrinogen; Glycosaminoglycans; Humans; Hyperlipidemias; Male; Middle Aged; Triglycerides; Vascular Diseases

Topics: Arteriosclerosis; Clinical Trials as Topic; Coronary Disease; Female; Glycosaminoglycans; Humans; Hyperlipidemias; Hypolipidemic Agents; Intracranial Arteriosclerosis; Male

The authors tested the efficacy of three different lipid-lowering drugs in subjects with more or less severe alterations of the lipoprotein pattern. All subjects were submitted to blood tests prior to and at the end of treatment with special attention to the trend of the lipid pattern, assaying cholesterol, HDL, LDL, triglyceride, total lipid blood levels and lipid electrophoresis. The drugs employed were: pantothenic acid, sulodexide, and DEAE-dextran.

Topics: Adult; DEAE-Dextran; Female; Glycosaminoglycans; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Outpatients; Pantothenic Acid; Triglycerides

Topics: Adult; Aged; Drug Evaluation; Female; Glycosaminoglycans; Hearing Loss, Sensorineural; Humans; Hyperlipidemias; Hyperlipoproteinemias; Labyrinth Diseases; Male; Middle Aged; Tinnitus; Vertigo